This study is designed to learn more about how oleclumab in combination with durvalumab or monalizumab in combination with durvalumab, each given after completion of concurrent chemoradiotherapy (chemotherapy and radiation at the same time) in stage III NSCLC might provide benefit to participants, and also to better understand the disease and associated health problems.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 3 Drug TrialLate stage studies conducted to confirm efficacy and safety of investigational therapies in large patient populations prior to introduction to clinical practice.
-
ERM Project ID
82098
Trial contact details
-
Contact person
Stevie Anderson
-
Phone
0447 217 497
What you need to know
Who can take part?
Male and female participants aged ≥ 18 years with histologically or cytologically documented locally advanced (Stage III), unresectable NSCLC disease who have not progressed on prior platinum-based cCRT and who do not have EGFR mutations or ALK alterations.
Participants must have received at least 2 cycles of platinum-based chemotherapy concurrent with radiation therapy, which must be completed within 1 to 42 days prior to first dose of investigational product in the study.
What is involved?
Treatment Period: 15 Cycles up to 12 months
Your study doctor will also explain what you will have to do and the tests that you will have during the study. A brief overviews includes; blood tests, physical examination, vital signs, tumour Assessment (CT scan/MRI)/PET, Urine test, ECG, Questionnaire.
Trial dates
July 2022 - May 2025
